Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia

被引：16
|
作者：
Castillo, Jorge J. [1 ,2 ]
Gustine, Joshua N. [1 ]
Meid, Kirsten [1 ]
Dubeau, Toni E. [1 ]
Xu, Lian [1 ]
Yang, Guang [1 ,2 ]
Hunter, Zachary R. [1 ]
Advani, Ranjana [3 ]
Palomba, Lia [4 ]
Treon, Steven P. [1 ,2 ]
机构：
[1] Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
HAEMATOLOGICA | 2018年 / 103卷 / 10期
关键词：
MYD88;
D O I：
10.3324/haematol.2018.191999
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E466 / E468
页数：3
相关论文
共 50 条
  • [21] Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
    Abeykoon, Jithma Prasad
    Zanwar, Saurabh
    Ailawadhi, Sikander
    Larsen, Jeremy
    Gertz, Morie A.
    Gonsalves, Wilson I.
    Buadi, Francis K.
    Kumar, Shaji K.
    Rajkumar, S. Vincent
    King, Rebecca L.
    Inwards, David J.
    Lacy, Martha Q.
    Habermann, Thomas M.
    Dispenzieri, Angela
    Witzig, Thomas E.
    Leung, Nelson
    Hobbs, Miriam
    Dingli, David
    Kyle, Robert A.
    Ansell, Stephen M.
    Kapoor, Prashant
    BLOOD, 2018, 132
  • [22] Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia
    Gunaratne, Madugodaralalage D. S. K.
    Sahakian, Alexander J.
    Abeykoon, Jithma P.
    Ansell, Stephen M.
    Gertz, Morie A.
    Kapoor, Prashant
    Paulus, Aneel
    Ailawadhi, Sikander
    Reeder, Craig B.
    Witzig, Thomas E.
    Habermann, Thomas M.
    Novak, Anne J.
    Lacy, Martha Q.
    Kyle, Robert A.
    Go, Ronald S.
    Paludo, Jonas
    LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 308 - 315
  • [23] ADHERENCE AND DOSE INTENSITY FOLLOWING ADMINISTRATION OF THE IBRUTINIB 420 MG DOSE IN PATIENTS WITH PREVIOUSLY TREATED CLL
    Jaeger, U.
    Barr, P. M.
    Brown, J. R.
    Hillmen, P.
    O'Brien, S.
    Barrientos, J. C.
    Reddy, N. M.
    Coutre, S.
    Mulligan, S. P.
    Furman, R. R.
    Cymbalista, F.
    Montillo, M.
    Dearden, C.
    Robak, T.
    Moreno, C.
    Pagel, J. M.
    Burger, J. A.
    Suzuki, S.
    Sukbuntherng, J.
    Cole, G.
    James, D. F.
    Byrd, J. C.
    HAEMATOLOGICA, 2015, 100 : 155 - 155
  • [24] Bendamustine plus rituximab for the treatment of Waldenstrom Macroglobulinemia: Patient outcomes and impact of bendamustine dosing
    Arulogun, Suzanne O.
    Brian, Duncan
    Goradia, Harshita
    Cooney, Aaron
    Menne, Tobias
    Koo, RayMun
    O'Neill, Aideen T.
    Vos, Josephine M. I.
    Pratt, Guy
    Turner, Deborah
    Marshall, Kirsty
    Manos, Kate
    Anderson, Claire
    Gavriatopoulou, Maria
    Kyriakou, Charalampia
    Kersten, Marie J.
    Minnema, Monique C.
    Koutoumanou, Eirini
    El-Sharkawi, Dima
    Linton, Kim
    Talaulikar, Dipti
    McCarthy, Helen
    Bishton, Mark
    Follows, George
    Wechalekar, Ashutosh
    D'Sa, Shirley P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (05) : 750 - 759
  • [25] Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenstrom Macroglobulinemia on and off Clinical Trials
    Castillo, Jorge J.
    Gustine, Joshua N.
    Meid, Kirsten
    Flynn, Catherine A.
    Demos, Maria G.
    Guerrera, Maria L.
    Jimenez, Cristina
    Kofides, Amanda
    Liu, Xia
    Munshi, Manit
    Tsakmaklis, Nicholas
    Patterson, Christopher J.
    Xu, Lian
    Yang, Guang
    Hunter, Zachary R.
    Treon, Steven P.
    HEMASPHERE, 2020, 4 (03):
  • [26] Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: A report of 71 cases
    Leblond, V
    Ben-Othman, T
    Deconinck, E
    Taksin, AL
    Harousseau, JL
    Delgado, MA
    Delmer, A
    Maloisel, F
    Mariette, X
    Morel, P
    Clauvel, JP
    Duboisset, P
    Entezam, S
    Hermine, O
    Merlet, M
    Yakoub-Agha, I
    Guibon, O
    Caspard, H
    Fort, N
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) : 2060 - 2064
  • [27] Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenstrom macroglobulinemia (WM): Results from iNNOVATE.
    Tedeschi, Alessandra
    Dimopoulos, Meletios A.
    Trotman, Judith
    Garcia-Sanz, Ramon
    MacDonald, David
    Mahe, Beatrice
    Herbaux, Charles
    Heffner, Leonard T.
    Tam, Constantine Si Lun
    Varettoni, Marzia
    Palomba, Maria Lia
    Matous, Jeffrey
    Shustik, Chaim
    Kastritis, Efstathios
    Treon, Steven P.
    Li, Jianling
    Poulsen, Erik
    Hauns, Bernhard
    Buske, Christian
    Leblond, Veronique
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
    Barr, Paul M.
    Brown, Jennifer R.
    Hillmen, Peter
    O'Brien, Susan
    Barrientos, Jacqueline C.
    Reddy, Nishitha M.
    Coutre, Steven
    Mulligan, Stephen P.
    Jaeger, Ulrich
    Furman, Richard R.
    Cymbalista, Florence
    Montillo, Marco
    Dearden, Claire
    Robak, Tadeusz
    Moreno, Carol
    Pagel, John M.
    Burger, Jan A.
    Suzuki, Samuel
    Sukbuntherng, Juthamas
    Cole, George
    James, Danelle F.
    Byrd, John C.
    BLOOD, 2017, 129 (19) : 2612 - 2615
  • [29] Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenstrom macroglobulinemia: Patient case report
    Hartsell, Lauren
    Janes, Amanda
    Larck, Chris
    Park, Steven
    Arnall, Justin R.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) : 1534 - 1539
  • [30] Real-world data of zanubrutinib treatment for patients with previously treated Waldenstrom Macroglobulinemia
    Jang, Seo Yoon
    Kwon, Soyean
    Byun, Ja Min
    Koh, Youngil
    Hong, Junshik
    Yoon, Sung-Soo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S277 - S277
12345